MediWound (NASDAQ:MDWD) Shares Cross Above 50 Day Moving Average – Should You Sell?

MediWound Ltd. (NASDAQ:MDWD)’s share price passed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $13.05 and traded as high as $13.67. MediWound shares last traded at $13.56, with a volume of 126,554 shares traded.

Analyst Ratings Changes

A number of equities research analysts have recently commented on MDWD shares. TD Cowen reaffirmed a “buy” rating on shares of MediWound in a research note on Thursday, September 24th. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. Alliance Global Partners reissued a “buy” rating on shares of MediWound in a report on Wednesday, September 16th. Oppenheimer restated an “outperform” rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Finally, Weiss Ratings lowered shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $33.00.

MediWound Stock Up 8.0%

The firm has a market cap of $174.27 million, a price-to-earnings ratio of -7.53 and a beta of 0.09. The company’s 50-day moving average price is $13.05 and its 200-day moving average price is $15.28.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The company had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. Analysts predict that MediWound Ltd. will post -2.37 earnings per share for the current fiscal year.

Insider Transactions at MediWound

In other MediWound news, COO Shmuel Hess sold 3,958 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.20% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.